GleamWall
中文EN

NTLA Intellia Therapeutics, Inc.

In Vitro & In Vivo Diagnostic Substances · Nasdaq · SEC CIK 1652130 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-8.1%
TTM net income YoY4.4%
TTM EPS YoY21.2%
Revenue 3-yr CAGR77.2%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-821.2%
Net margin-805.7%
FCF margin-677.1%
EBITDA margin-805.0%

Returns

ROE-62.6%
ROA-46.6%
ROIC (approx.)-63.2%
Asset turnover0.06x

Leverage & solvency

Liabilities / assets32.1%
Debt / equity0.12x
Current ratio6.31x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.83x
Accruals ratio-7.8%
Payout ratio—
Capex / revenue5.5%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$7.16M$7.66M$15.05M$23.02M$13.78M$14.24M$16.63M$12.87M
R&D expense$83.35M$82.59M$80.74M$88.65M$94.75M$97.03M$108.43M$116.88M
SG&A expense$46.14M$37.82M$34.84M$33.08M$30.51M$27.21M$29.01M$32.44M
Operating income-$122.33M-$112.76M-$100.53M-$98.71M-$111.48M-$110.00M-$120.81M-$136.45M
Interest expense$611,000———$0———
Net income-$127.48M-$106.63M-$96.23M-$95.79M-$101.32M-$101.25M-$114.33M-$128.90M
EBITDA-$120.42M-$110.66M-$98.33M-$96.33M-$109.08M-$107.50M-$118.31M-$133.88M
EPS (basic)-0.91-0.80-0.81—-0.92-0.98-1.10—
EPS (diluted)-0.91-0.80-0.81—-0.92-0.98-1.10—
Weighted avg. shares (diluted)140.19M133.48M118.49M—110.19M103.73M103.50M—
Balance sheet
Cash & equivalents$156.10M$106.13M$134.70M$155.46M$193.39M$156.17M$126.88M$189.18M
Short-term investments$318.01M$331.63M$241.29M$294.42M$317.65M$303.48M$376.87M$412.33M
Receivables$7.50M$7.32M$9.13M$9.47M$11.05M$11.35M$10.50M$8.52M
Current assets$506.35M$527.83M$466.45M$527.71M$581.94M$495.94M$551.39M$639.86M
PP&E, net$13.92M$15.06M$15.52M$17.67M$20.42M$22.81M$25.12M$27.38M
Total assets$902.56M$857.16M$758.78M$842.13M$925.27M$898.89M$986.16M$1.19B
Current liabilities$80.31M$79.39M$76.44M$103.88M$93.73M$95.50M$112.59M$110.85M
Long-term debt$73.73M——$0————
Total debt$73.73M——$0————
Total liabilities$289.47M$129.46M$137.84M$170.73M$176.85M$183.64M$206.24M$319.06M
Shareholders' equity$613.09M$727.71M$620.94M$671.39M$748.42M$715.25M$779.92M$871.96M
Net debt-$82.37M——-$155.46M————
Shares outstanding140.25M140.02M120.45M116.32M115.79M105.33M103.54M102.03M
Cash flow statement
Operating cash flow-$85.43M-$83.11M-$117.35M-$69.28M-$76.90M-$99.62M-$148.93M-$85.19M
Capital expenditure$888,000$1.81M$79,000$126,000$29,000$239,000$735,000$981,000
Free cash flow-$86.32M-$84.92M-$117.42M-$69.41M-$76.93M-$99.86M-$149.66M-$86.18M
Investing cash flow$61.94M-$141.57M$66.31M$27.53M-$741,000$106.91M$94.33M$151.56M
Financing cash flow$73.46M$196.12M$33.57M$1.98M$114.86M$14.65M$0$2.32M
Depreciation & amortization$1.90M$2.10M$2.20M$2.38M$2.40M$2.50M$2.50M$2.57M
Stock-based compensation$14.40M$18.07M$13.48M$16.74M$19.60M$22.04M$21.84M$39.62M

Free plan shows the latest 8 periods; Pro shows all 47 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.